 |
Diseases |  |
Trials |
|
Trials |  |
News |  |
- | HLX70 - Fosun Pharma, ZJ Bio / Tech
Journal: Exploring the Binding Affinity and Mechanism between ACE2 and the Trimers of Delta and Omicron Spike Proteins by Molecular Dynamics Simulation and Bioassay. (Pubmed Central) - Sep 29, 2022
The experimentally determined K values by biolayer interferometry (BLI) and the predicted binding free energies of the RBDs of Delta and Omicron to mAb HLX70 revealed that the two variants may have the high risk of immune evasion from the mAb. These results are not only helpful in understanding the binding strength and mechanism of S protein trimer-ACE2 but also beneficial for drug, especially for antibody development.
- HLX70 - Fosun Pharma, ZJ Bio / Tech
New P1 trial: Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers (clinicaltrials.gov) - Jun 23, 2022
P1, N=0, Withdrawn, Sponsor: Shanghai Henlius Biotech
- | HLX70 - Fosun Pharma, ZJ Bio / Tech
Enrollment change, Trial withdrawal: Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers (clinicaltrials.gov) - Apr 1, 2022
P1, N=0, Withdrawn, Sponsor: Hengenix Biotech Inc
These results are not only helpful in understanding the binding strength and mechanism of S protein trimer-ACE2 but also beneficial for drug, especially for antibody development. N=24 --> 0 | Not yet recruiting --> Withdrawn
- | HLX70 - Fosun Pharma, ZJ Bio / Tech
New P1 trial: Evaluate Safety and Pharmacokinetics of HLX70 in Healthy Adult Volunteers (clinicaltrials.gov) - Sep 22, 2020
P1, N=24, Not yet recruiting, Sponsor: Hengenix Biotech Inc